Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population
Status:
Terminated
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in
addition to best supportive care is effective in prolonging the lives of Asian subjects with
unresectable stage III non-small cell lung cancer in comparison to a placebo plus best
supportive care (a so-called placebo controlled study).